Literature DB >> 10576511

ABL-BCR expression in BCR-ABL-positive human leukemia cell lines.

C C Uphoff1, S Habig, S Fombonne, Y Matsuo, H G Drexler.   

Abstract

Expression of normal ABL and BCR and of reciprocal fusion genes BCR-ABL and ABL-BCR was examined in a panel of 53 BCR-ABL-positive cell lines by RT-PCR to determine the influence of the various transcripts on leukemogenesis. Seventeen out of 18 lymphoid cell lines expressed ABL1a and/or ABL1b, whereas only 16 out of 35 myeloid cell lines expressed one or both normal ABL transcripts. Normal BCR was expressed in seven lymphoid cell lines; all cell lines from the m-bcr group (n = 9) were BCR-negative. Among the myeloid cell lines, 77% expressed the BCR gene. The M-bcr and m-bcr translocations were equally distributed among cell lines with lymphoid phenotype. The m-bcr translocation was not found in myeloid cell lines. b3-a2 constitutes the predominant form of fusion gene in myeloid cell lines with an incidence of about 68%. One myeloid cell line exhibited the mu-bcr variant. An ABL-BCR transcript of the 1a splice variant was not detected in any of the cell lines. ABL1b-BCR was expressed in all varieties of cell types and translocation forms: 56 and 66% in the lymphoid and myeloid cell lines, respectively; similar distributions were found for the fusion gene types: 67% among e1-a2, 73% among b2-a2, and 61% among b3-a2 translocations. Except for the lack of expression of normal BCR in m-bcr cell lines and of ABL1a-BCR expression in all cell lines, no consistent correlation of expression or lack of expression of BCR and ABL or of ABL-BCR reciprocal fusion genes could be found with cell lineages and translocation types. Further work is required to determine the exact role of the reciprocal fusion gene transcripts on the pathophysiological mechanisms of leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10576511     DOI: 10.1016/s0145-2126(99)00131-9

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

1.  Quantitative intra-individual monitoring of BCR-ABL transcript levels in archival bone marrow trephines of patients with chronic myeloid leukemia.

Authors:  Oliver Bock; Ulrich Lehmann; Hans Kreipe
Journal:  J Mol Diagn       Date:  2003-02       Impact factor: 5.568

2.  A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.

Authors:  Jonathan A Webster; Tara M Robinson; Amanda L Blackford; Erica Warlick; Anna Ferguson; Ivan Borrello; Marianna Zahurak; Richard J Jones; B Douglas Smith
Journal:  Leuk Res       Date:  2021-11-02       Impact factor: 3.156

3.  A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates.

Authors:  Ding Wu; Michael R Mand; Darren R Veach; Laurie L Parker; Bayard Clarkson; Stephen J Kron
Journal:  Anal Biochem       Date:  2007-12-25       Impact factor: 3.365

4.  BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

Authors:  Hilmar Quentmeier; Sonja Eberth; Julia Romani; Margarete Zaborski; Hans G Drexler
Journal:  J Hematol Oncol       Date:  2011-02-07       Impact factor: 17.388

5.  Evaluating translocation gene fusions by SNP array data.

Authors:  Hong Liu; Asher Zilberstein; Pascal Pannier; Frederic Fleche; Christopher Arendt; Christoph Lengauer; Chang S Hahn
Journal:  Cancer Inform       Date:  2011-12-21

6.  Genome Fusion Detection: a novel method to detect fusion genes from SNP-array data.

Authors:  Sebastian Thieme; Philip Groth
Journal:  Bioinformatics       Date:  2013-01-22       Impact factor: 6.937

7.  Synthesis, Structural Characterization, and Cytotoxic Activity of Novel Paramagnetic Platinum Hematoporphyrin IX Complexes: Potent Antitumor Agents.

Authors:  G Gencheva; D Tsekova; G Gochev; G Momekov; G Tyuliev; V Skumryev; M Karaivanova; P R Bontchev
Journal:  Met Based Drugs       Date:  2007

8.  Molecular Genetics of Pre-B Acute Lymphoblastic Leukemia Sister Cell Lines during Disease Progression.

Authors:  Hilmar Quentmeier; Claudia Pommerenke; Hans G Drexler
Journal:  Curr Issues Mol Biol       Date:  2021-11-30       Impact factor: 2.976

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.